Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Düsing, R.
Right arrow Articles by Lehnert, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Düsing, R.
Right arrow Articles by Lehnert, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2004) 19: 531-534
Nephrol Dial Transplant Vol. 19 No. 3 (c) ERA-EDTA 2004; all rights reserved

Editorial Comment

Diabetogenic effect of antihypertensive treatment: primum nil nocere

Rainer Düsing1 and Hendrik Lehnert2

1Universitätsklinikum Bonn, Medizinische Universitäts-Poliklinik and 2Zentrum für Innere Medizin, Klinik für Endokrinologie und Stoffwechselkrankheiten, Magdeburg, Germany

Correspondence and offprint requests to: Professor Dr Rainer Düsing, Universitätsklinikum Bonn, Medizinische Universitäts-Poliklinik, Wilhelmstrasse 35–37, D-53111 Bonn, Germany. Email: duesing@uni-bonn.de

Keywords: ACE inhibitors; antihypertensive therapy; AT1-antagonists; ß-blockers; Ca-channel blockers; diuretics; new-onset diabetes

The first 10% of the full text of this article appears below.



   Introduction
 
Hypertension and diabetes mellitus have been shown to exhibit a complex and multifactorial interrelationship. As part of this, the incidence of diabetes is enhanced in hypertensive patients and this finding is only in part explained by the higher percentage of overweight and obese patients in both populations [1–3]. Moreover, evidence suggests that the rate of new-onset diabetes mellitus in hypertensive patients may also depend on the choice of antihypertensive treatment [4–15]. Among the more modern trials comparing antihypertensive treatment strategies, the Captopril Prevention Project (CAPPP) observed a statistically higher rate of new-onset diabetes in patients randomized to . . . [Full Text of this Article]



   Evidence from randomized controlled trials
 


   Clinical significance
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?